Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes

Anticipated Profits From Biosimilar Candidates To Expand Future Development

 
• By Chloe Kent
  
Gloved hand holding a vial and syringe
The two biosimilars should give Formycon's biosimilar business a significant boost • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products